Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain

G. Villa; L. J. Hernández-Pastor; M. Guix; J. Lavernia; M. Cuesta

首页> 外文期刊>Clinical and Translational Oncology >Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain

【24h】

Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain

机译：帕唑帕尼在西班牙晚期软组织肉瘤二线治疗中的成本效益分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose To assess the efficiency of pazopanib compared with trabectedin in the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) after chemotherapy failure.

机译：目的评估帕唑帕尼与曲贝替丁治疗成人化疗失败后亚型选择性软组织肉瘤（STS）亚型的疗效。

著录项

来源
《Clinical and Translational Oncology》 |2015年第1期|24-33|共10页
作者
G. Villa; L. J. Hernández-Pastor; M. Guix; J. Lavernia; M. Cuesta;
展开▼
作者单位

Health Economics GlaxoSmithKline">(1);

Health Economics GlaxoSmithKline">(1);

Medical Oncology Hospital del Mar">(2);

Medical Oncology Instituto Valenciano de Oncología">(3);

Health Economics Oblikue Consulting">(4);

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
Soft-tissue sarcoma; Pazopanib; Trabectedin; Cost-effectiveness analysis;

机译：软组织肉瘤;帕唑帕尼;特拉贝丁成本效益分析;

相似文献

外文文献
中文文献
专利

1. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain [J] . Villa G., Hernandez-Pastor L. J., Guix M., Clinical & translational oncology : . 2015,第1期

机译：帕唑帕尼在西班牙晚期软组织肉瘤二线治疗中的成本效益分析
2. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). [J] . Sleijfer S, Ray Coquard I, Papai Z Journal of Clinical Oncology . 2009,第19期

机译：Pazopanib是一种多激酶血管生成抑制剂，用于患有复发性或难治性晚期软组织肉瘤的患者：来自欧洲组织的研究和治疗癌症软组织和骨肉瘤组的II期研究（EORTC研究62043）。
3. Cost-effectiveness of pazopanib in advanced soft-tissue sarcoma in Canada [J] . A. Chit, A. Wang, H.R. Nakhaipour, Current oncology . 2014,第6期

机译：帕唑帕尼治疗加拿大晚期软组织肉瘤的成本效益
4. A quantitative histogram-based approach to predict treatment outcome for Soft Tissue Sarcomas using pre- and post-treatment MRIs [C] . Hamidreza Farhidzadeh, Dmitry B. Goldgof, Lawrence O. Hall, IEEE International Conference on Systems, Man, and Cybernetics . 2016

机译：基于定量直方图的方法，使用治疗前和治疗后MRI预测软组织肉瘤的治疗结果
5. Treatment Patterns and Cost-Effectiveness of Chemotherapy Treatments among Advanced Gastric Cancer Patients [D] . Haag, Austin Jade. 2017

机译：晚期胃癌患者化学疗法的治疗模式和成本效益
6. Cost-Effectiveness of Pazopanib in Advanced Soft Tissue Sarcoma in the United Kingdom [O] . Jordan Amdahl, Stephanie C. Manson, Robert Isbell, 2014

机译：帕唑帕尼在英国晚期软组织肉瘤中的成本效果
7. Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials [O] . Melissa Vos, Stefan Sleijfer, Saskia Litière, 2019

机译：Pazopanib诱导的毒性与晚期软组织肉瘤患者的结果;基于欧洲癌症（EORTC）62043和62072临床试验的欧洲研究和治疗组织的回顾性分析

Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain

摘要

著录项

相似文献

相关主题

期刊订阅